Get to know our clinical trials
Atacicept in multiple glomerular diseases.
Status
In recruitment
headquarters
Pamplona
Early phase
Technical Summary
- PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ATACICEPT IN MULTIPLE GLOMERULAR AUTOIMMUNE DISEASES (PIONEER).
- Code EudraCT: 2024-518465-10
- Protocol number: VT-001-0060
- Promoter: Vera Therapeutics
- Molecule/Drug: Atacicept
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.